|
Synonyms: 9F3v13 | RhuMAB IFNalpha | rhuMAb interferon-α
Compound class:
Antibody
Comment: Rontalizumab is a humanized monoclonal antibody targeting interferon alpha (IFNα) that has immunomodulatory potential. It was humanized from a mouse monoclonal as described in [2], and peptide sequences of the antibody (identified as humanized 9F3v13) are claimed in Genentech patent US7582445 [1].
Rontalizumab is functionally similar to sifalimumab. Development of both of these anti-IFNα agents has been discontinued. Compare these with anifrolumab, which targets the type I interferon receptor (IFNAR1) rather than the ligand itself, and which has progressed to Phase 3 clinical trial. A 3D X-ray structure of rontalizumab's Fab domain bound to IFNα2 has been published (PDB identifier 4Z5R) [5]. |
| No information available. |
Summary of Clinical Use  |
| Clinical development was discontinued after a failure to show efficacy in a Phase 2 clinical trial (NCT00962832) in patients with systemic lupus erythematosus (SLE) [4]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00962832 | A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 2 Interventional | Genentech, Inc. | ||
